Company Profile - Myovant Sciences Ltd

Introduction

Myovant Sciences Ltd (Myovant), a subsidiary of Sumitovant Biopharma Ltd, is a biopharmaceutical company that develops and commercializes new treatments for women’s diseases and endocrine disorders. The company’s products include relugolix, an oral small molecule that functions as a gonadotropin-releasing hormone receptor antagonist targeting conditions such as heavy menstrual bleeding associated with uterine fibroids. In addition, it also offers MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of the hormonal preparation in assisted reproduction. The company has operations in the US, Ireland, and Switzerland. Myovant is headquartered in London, the UK.